A detailed history of Hollencrest Capital Management transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Hollencrest Capital Management holds 500 shares of EDIT stock, worth $1,330. This represents 0.0% of its overall portfolio holdings.

Number of Shares
500
Previous 615 18.7%
Holding current value
$1,330
Previous $2,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

SELL
$3.39 - $5.96 $389 - $685
-115 Reduced 18.7%
500 $1,000
Q4 2022

Feb 06, 2023

BUY
$8.32 - $13.21 $5,116 - $8,124
615 New
615 $5,000

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $183M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Hollencrest Capital Management Portfolio

Follow Hollencrest Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hollencrest Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Hollencrest Capital Management with notifications on news.